These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25450152)

  • 21. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study.
    Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
    Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
    Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy.
    Eoh KJ; Yoon JW; Lee I; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    J Surg Oncol; 2017 Sep; 116(3):329-336. PubMed ID: 28542980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.
    Ebata T; Yunokawa M; Yoshida H; Bun S; Shimoi T; Shimomura A; Kodaira M; Yonemori K; Shimizu C; Fujiwara Y; Kato T; Tamura K
    Int J Gynecol Cancer; 2017 Nov; 27(9):1850-1855. PubMed ID: 29040183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital.
    van Vliet MM; Schreuder HW; Pasker-de Jong PC; Duk MJ
    Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():72-8. PubMed ID: 26177496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
    Mueller JJ; Kelly A; Zhou Q; Iasonos A; Long Roche K; Sonoda Y; O'Cearbhaill RE; Zivanovic O; Chi DS; Gardner GJ
    Gynecol Oncol; 2016 Dec; 143(3):496-503. PubMed ID: 27692668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy.
    Baek MH; Lee SW; Park JY; Rhim CC; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    Int J Gynecol Cancer; 2017 Mar; 27(3):420-429. PubMed ID: 28187098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
    Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.
    Chern JY; Curtin JP
    Curr Treat Options Oncol; 2016 Jan; 17(1):1. PubMed ID: 26714493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer.
    Son JH; Chang K; Kong TW; Paek J; Chang SJ; Ryu HS
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1294-1301. PubMed ID: 29683235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of immediate re-operation or interval debulking after chemotherapy at a gynecologic oncology center after initially incomplete cytoreduction of advanced ovarian cancer.
    Grabowski JP; Harter P; Hils R; Lorenz D; Kaub C; Barinoff J; Heitz F; Traut A; du Bois A
    Gynecol Oncol; 2012 Jul; 126(1):54-7. PubMed ID: 22472462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Surgery for advanced stage ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
    Ferron G; Narducci F; Pouget N; Touboul C
    Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):197-213. PubMed ID: 30792175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
    Becker DA; Thomas ED; Gilbert AL; Boone JD; Straughn JM; Huh WK; Bevis KS; Leath CA; Alvarez RD
    Gynecol Oncol; 2016 Jul; 142(1):25-29. PubMed ID: 27130405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer.
    Taşkın S; Güngör M; Ortaç F; Öztuna D
    Arch Gynecol Obstet; 2013 Dec; 288(6):1399-403. PubMed ID: 23775264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.
    Loizzi V; Leone L; Camporeale A; Resta L; Selvaggi L; Cicinelli E; Cormio G
    Oncology; 2016; 91(4):211-216. PubMed ID: 27487241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
    Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
    Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemotherapy in gynaecological cancers - Implications for staging.
    Kumar L; Pramanik R; Kumar S; Bhatla N; Malik S
    Best Pract Res Clin Obstet Gynaecol; 2015 Aug; 29(6):790-801. PubMed ID: 25840650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.